Aurora Cannabis NYSE: ACB
Aurora Cannabis Inc. produces and distributes medical cannabis products.
Name | Aurora Cannabis |
Ticker | ACB |
Exchange | NYSE |
Sector | Health Care |
Industry | Cannabis Specialties |
Price | 10.16 |
52W Low/High | 3.83 / 25.68 |
Market cap | 1.2 B |
1Y Total Return |
-57.45%
Weak |
1Y Volatility |
145.28%
High Risk |
Relative Strength Index : Attempt to identify overbought (above 80) and oversold (below 20) conditions
Aurora Cannabis Inc. produces and distributes medical cannabis products.
Details
Ticker | ACB |
Name | Aurora Cannabis |
ISIN | |
CUSIP | |
Exchange | NYSE |
Sector | Health Care |
Industry | Cannabis Specialties |
Country | Canada |
Currency | U.S. Dollar |
Share as of 1/25/21
Close Price | 10.16 |
52W Low/High | 3.83 / 25.68 |
Market cap | 1.2 B |
1Y Total Return |
-57.45%
Weak |
1Y Volatility |
145.28%
High Risk |
Beta | 3.16 |
PE (trailing) | - |
12M Dividends | - |
Last Dividend Date | - |
Dividend Yield | - |
Fin. Strength
Net Profit Margin | -1,282.2% |
Cash from Op. / Cur. Liabilities | -1.53 |
Diluted Earnings / Share | - |
ROE | - |
ROIC | -70.5% |
Price / Revenue | - |
Price / Book | - |
Price / CF | - |
Current Ratio | 1.9 |
Cur.Liabilities / Tot.Liabilities | 0.4 |
Financial Leverage | 0.24 |
in Mils USD |
rolling-year up to September
|
||||
---|---|---|---|---|---|
Income Statement | 2020 | 2019 | 2018 | 2017 | |
Revenue |
204
|
221
|
58
|
-
|
|
Gross Profit |
-
|
136
|
32
|
-
|
|
R&D |
17
|
13
|
4
|
-
|
|
EBITDA |
-2,551
|
-170
|
172
|
-
|
|
Operating Income |
-343
|
-217
|
-156
|
-
|
|
Net Income exc. Extra |
-
|
-
|
123
|
-
|
|
per Share | |||||
Diluted avg Shares |
-
|
-
|
-
|
-
|
|
EPS exc. Extra |
-
|
-3.61
|
2.45
|
-
|
|
Dividend |
-
|
-
|
-
|
-
|
|
Div. Yield (an.) |
-
|
-
|
-
|
-
|
|
Balance Sheet | 2020 | 2019 | 2018 | 2017 | |
Total Assets |
2,073
|
4,280
|
3,754
|
-
|
|
Cash, Eq & Invt ShortTerm |
123
|
189
|
375
|
-
|
|
Total Current Assets |
324
|
449
|
490
|
-
|
|
Total Non-Current Assets |
1,749
|
3,831
|
3,264
|
-
|
|
Intangibles |
997
|
2,943
|
2,650
|
-
|
|
Total Liabilities |
454
|
871
|
419
|
-
|
|
Total Current Liabilities |
172
|
355
|
75
|
-
|
|
Long Term Debt |
281
|
516
|
344
|
-
|
|
Shareholder equity |
1,620
|
3,410
|
3,333
|
-
|
|
Cash Flow | 2020 | 2019 | 2018 | 2017 | |
Cash from Operations |
-264
|
-166
|
-110
|
-
|
|
Depreciation |
84
|
78
|
21
|
-
|
|
Cash from Investing |
-175
|
-279
|
-367
|
-
|
|
Capex |
194
|
343
|
142
|
-
|
|
Cash from Financing |
432
|
455
|
484
|
-
|
|
Stock Issued |
475
|
69
|
183
|
-
|
|
Debt (LT) Issued |
-75
|
421
|
320
|
-
|
|
Free Cash Flow |
-2,235
|
-45
|
-
|
-
|
|
Ratios | 2020 | 2019 | 2018 | 2017 | |
Net Profit Margin |
-
|
-
|
211.2%
|
-
|
|
NCFO / Op.Income |
-
|
-
|
-
|
-
|
|
Current Ratio |
1.9
|
1.3
|
6.5
|
-
|
|
Financial Leverage D/E |
0.24
|
0.18
|
0.07
|
-
|
|
Return on Capital Avg |
-70.5%
|
-5.2%
|
7.6%
|
-
|
|
Return on Shareholder Equity |
-
|
-
|
-
|
-
|
Fundamentals
No documents are available for the moment, please check back soon, or save the asset to be notified when documents are available